At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 24 enrolled
Drug / intervention
Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)drug
Likely dose
Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C) 800mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Reducing Frailty for Older Cancer Survivors Using Supplements (ReFOCUS): A Pilot Randomized Controlled Trial of the Feasibility, Safety, and Preliminary Effects of Epigallocatechin-3-Gallate (EGCG) in Pre-Frail and Frail Older Cancer Survivors
In Brief
A Phase 2 clinical trial evaluating Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C) for Frailty and Inflammation. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study is to examine the feasibility and safety of twelve weeks oral supplementation of Epigallocatechin-3-gallate (EGCG) in older survivors of cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFrailty, Inflammation
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartApr 2021
Primary CompletionAug 2023
TodayJul 2026
First PostedSep 17, 2020
Enrollment StartApr 28, 2021
Primary CompletionAug 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.8 years ago
Interventions
Epigallocatechin-3-Gallate (EGCG) plus Ascorbic Acid (Vitamin C)drug
800mg Epigallocatechin-3-Gallate (EGCG) plus 250mg Ascorbic Acid (Vitamin C) taken one time a day for twelve weeks